HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- ‘There needs to be urgency’ to address late endocrinopathies in childhood cancer survivors
-
- Should pediatric cancer survivors previously exposed to neck irradiation undergo ultrasound screening for thyroid cancer?
- Saying goodbye John Sweetenham, MD, FRCP, FACP
- Pembrolizumab reduces mortality risk in advanced PD-L1-positive esophageal cancer
- Conservative management becomes most common approach for low-risk prostate cancer
- Targeted radiation therapy yields high response rates in metastatic prostate cancer
- Delayed initiation of adjuvant chemotherapy linked to poorer outcomes in triple-negative breast cancer
- B-cell maturation antigen-targeted CAR T-cell therapy potent in advanced myeloma
- Gene therapy shows long-term activity in severe hemophilia B
-
- Ibrutinib plus CD19-specific CAR T-cell therapy may benefit patients with relapsed or refractory CLL
- HOPA Ahead 2019 to help hematology/oncology pharmacists deliver highest-quality care
- Women with HPV without cellular abnormalities at increased risk for cervical cancer
- Patient sex does not influence immunotherapy efficacy
- Brentuximab vedotin data ‘practice changing’ for older patients with Hodgkin lymphoma
- 23andMe receives FDA clearance for hereditary colorectal cancer syndrome genetic test
- FDA places partial hold on phase 3 trial of axalimogene filolisbac for cervical cancer
- Task force: Medications to reduce breast cancer risk ‘are not for everyone’
-
- USPSTF maintains stance against pancreatic cancer screening in asymptomatic adults